# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Rodman & Renshaw analyst Brandon Folkes reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $16 price t...
- Reuters Citing State TV
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it was awarded a contract modification executing an option period by...
- Reuters
https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926 Senior Biden administrati...
https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523 Today, close to 100,000 mpox vaccine doses will arrive in the ...
The New Term Loan maturity extends up to five years, through August 2029. Excess proceeds from the refinancing will result in a...